Effect of Orlistat on Fecal Fat, Fecal Biliary Acids, and Colonic Cell Proliferation in Obese Subjects Dennis J. Ahnen, Roberto Guerciolini, Jonathan Hauptman, Steven Blotner, Cindy J. Woods, Michael J. Wargovich Clinical Gastroenterology and Hepatology Volume 5, Issue 11, Pages 1291-1299 (November 2007) DOI: 10.1016/j.cgh.2007.07.009 Copyright © 2007 AGA Institute Terms and Conditions
Figure 1 Total crypt scores (mean ± SD) defined as labeling index for BrdU and PCNA and as mitoses per crypt for WCMC at baseline and after 6 weeks of treatment with placebo or orlistat 120 mg 3 times daily. Clinical Gastroenterology and Hepatology 2007 5, 1291-1299DOI: (10.1016/j.cgh.2007.07.009) Copyright © 2007 AGA Institute Terms and Conditions
Figure 2 Mean change from baseline in (A) BrdU, (B) PCNA, and (C) WCMC compartmental scores after 6 weeks of treatment with placebo (○) or orlistat (■) 120 mg 3 times daily. Clinical Gastroenterology and Hepatology 2007 5, 1291-1299DOI: (10.1016/j.cgh.2007.07.009) Copyright © 2007 AGA Institute Terms and Conditions